Clinical trial · Observational
Postoperative Pain Management on Patients Undergoing Lung Tumor Resection
Postoperative Pain Management on Patients Undergoing Video-assisted Thoracoscopic (VATS) Lung Tumor Resection: a Prospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Multimodal analgesia (MMA) is an essential part of Enhanced Recovery After Surgery (ERAS) protocol. The principle of MMA is to manage pain with analgesics of multiple classes acting on distinct target sites through different strategies. MMA can reduce the adverse reaction caused by opioids and improve the quality of recovery from surgery. Inadequate postoperative pain management will increase the risk of complications, including pneumonia, deep vein thrombosis, infection, delayed surgical healing, and chronic postoperative pain.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Tumor | Lung Neoplasm | ALIAS | 0.90 |
| Postoperative Pain | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Analgesic injectables | Drug | — | UNRESOLVED |
| Dinalbuphine sebacate | Drug | — | UNRESOLVED |
| Enteral analgesics | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- NALDEBAIN
- description
- Patients injected with dinalbuphine sebacate intramuscularly will be allocated to NALDEBAIN group.
- interventionNames
- Drug: Dinalbuphine sebacate
- Drug: Analgesic injectables
- Drug: Enteral analgesics
- label
- CONTROL
- description
- Patients receiving postoperative pain management without dinalbuphine sebacate will be allocated to CONTROL group.
- interventionNames
- Drug: Analgesic injectables
- Drug: Enteral analgesics
Primary outcomes (1)
- measure
- Postoperative pain intensity
- timeFrame
- Within 3 days after surgery
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. aged above 18. 2. diagnosed as lung cancer. 3. planning to undergo primary, video-assisted thoracoscopic lung tumor resection. 4. American Society of Anesthesiology Physical Class 1\~3. Exclusion Criteria: 1. unable to take assessments of the endpoints. 2. having this surgery in an emergency. 3. surgery involving other orangs, such as esophagus and stomach. 4. severe abnormality of cardiac, hepatic, or renal function. 5. allergic to opioids. 6. allergic to NSAIDs. 7. diagnosed as chronic pain or chronic use of analgesics. 8. unsuitable for participation judged by investigator.
References
Publications (0)
Data not yet available